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are starting to bear fruit. Patients with high sun sensitivity
manage to better protect themselves from sun exposure but,
despite this, there is a strong need to reinforce sun exposure risk
awareness in the general population.
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OBJECTIVES: To examine the literature on impacted cerumen
with speciﬁc reference to pharmacological ceruminolytic agents,
its epidemiology and current management in primary care.
METHODS: A systematic literature review was undertaken by
an electronic search of the Medline, Embase, Health Star,
Current Contents, NHSEED and Cochrane databases. The
search terms for the database included “cerumen”, “ear wax”
and “hearing loss” and included papers published between
January 1, 1990 and July 31, 2002. RESULTS: Impacted
cerumen is commonly seen in primary care settings. Between 1.2
million and 3.5 million people in the UK suffer from impacted
cerumen. Moreover, 2.3 million people in the UK suffer cerumen
problems serious enough to warrant management, with approx-
imately four million ears being syringed annually. Impacted
cerumen causes unpleasant symptoms and is occasionally asso-
ciated with serious sequale, such as hearing loss, social with-
drawal, poor work function and perforated eardrums. The
physiology, clinical signiﬁcance and management implications
associated with excessive and impacted cerumen remain poorly
characterised. The evidence supporting the traditional view that
cerumen plays a biologically or clinically signiﬁcant role in host
defence is weak; rather the consensus seems to be that if any-
thing, cerumen offers a rich medium supporting microbiological
growth. CONCLUSIONS: Patients with impacted cerumen
clearly require effective treatment. However, given a dearth of
rigorous evidence in the literature any attempt at a systematic
assessment of optimal management strategies is exceedingly dif-
ﬁcult. The evidence surrounding the pharmacological manage-
ment of impacted cerumen is inconsistent and few conclusions
can be drawn. There is clearly a need for a deﬁnitive assessment
of the most effective pharmacological strategy for cerumen
removal. Lastly, the causes and management of impacted
cerumen require further investigation.
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OBJECTIVES: Investigate whether methods employed to reduce
omitted variable bias can be used in a cross-sectional database
to identify a relationship between supplemental vitamin usage
and the presence of Age-related Macular Degeneration (AMD)
in a Latino population. METHODS: Data were obtained from
the Los Angeles Latino Eye Study (LALES) and included 6104
subjects. Data were originally collected to assess the prevalence
of ocular disease and diabetes. Stepwise logistic regressions and
simple logistic regressions for AMD were performed. Propensity
scores were then used to control for selection bias. In the ﬁrst
stage, the probability of receiving vitamin supplements for 10
years or more was modeled using logistic regression. Subjects
were separated into quintiles deﬁned by their propensity scores
and we compared the vitamin supplement/no vitamin supple-
ment groups using a 2-way analysis of variance model. Finally,
the effect of vitamin use on AMD after selection bias adjustment
was estimated using logistic regression. RESULTS: In total, 572
cases of AMD were identiﬁed. When using stepwise logistic
regression, older subjects (OR: 1.043, CI: 1.034–1.052), males
(1.624, 1.157–2.280), and people with income level less than
$20,000 (1.428, 1.006–2.028) were more likely to develop
AMD. Only age and gender were signiﬁcant using logistic regres-
sion and adjusting for potential confounders. The seven covari-
ates found signiﬁcantly different between the vitamin/no vitamin
groups were all non signiﬁcantly different after adjustment for
propensity score quintiles. However, even after selection bias
adjustment, vitamin usage continues to be non-signiﬁcant
(0.896, 0.594–1.352). CONCLUSIONS: Although, propensity
scores helped reduce potential sources of bias in this cross-sec-
tional database, they did not improve the ability to detect a rela-
tionship between vitamin usage and AMD. Other sources of bias,
such as the inability to determine the time of development of
AMD, unknown dosages and speciﬁc vitamins used, could not
be addressed by the use of propensity scores.
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OBJECTIVES: On-demand proton pump inhibitor (PPI) main-
tenance therapy is recommended for patients with symptomatic
gastroesophageal reﬂux disease (GERD) in Italy who achieve
symptom remission after 4 weeks of continuous treatment. The
objectives of this analysis are to evaluate the costs to the health
care system (NHS) and to society and effectiveness (quality
adjusted life years) of on-demand maintenance therapy in
patients with symptomatic GERD. METHODS: Decision analy-
sis and Markov modelling of costs and effectiveness up to 12
months. Efﬁcacy data were extracted from seven placebo-
controlled trials; the primary outcome measure was time to treat-
ment discontinuation owing to relapse of symptoms, requiring
continuous therapy. Health state utilities were derived from a
previously published study and data on health care resource util-
isation were obtained from a prospective Italian study that 
followed 577 patients with functional dyspepsia for one year.
RESULTS: Differences in utility scores associated with each PPI,
ranging from 0.731 to 0.745 quality-adjusted life years, were not
statistically different. Annual expected cost, however, were sta-
tistically different among the different drugs and the following
cost-minimization raking was obtained for costs to the NHS and
to society, respectively: rabeprazole (181€, 295€), pantoprazole
(223€, 341€), lansoprazole (249€, 370€), omeprazole 10mg
(297€, 412€), esomeprazole (295€, 419€), omeprazole 20mg
(405€, 528€). Unit cost of PPI was the major determinant of cost
to the NHS, while productivity days lost due to symptoms was
the major determinant of cost to society. CONCLUSIONS:
